Impaired glucose tolerance and incretins in chronic liver disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 2, 2008, Pages 166-167

  Gorrell, Mark D ^a,b  

^a University of Sydney   (Australia)

^b CENTENARY INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; EXENDIN 4; INCRETIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SITAGLIPTIN; TETRAHYDROLIPSTATIN;

CHRONIC LIVER DISEASE; CLINICAL FEATURE; DIABETES CONTROL; DIABETES MELLITUS; EDITORIAL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; PRIORITY JOURNAL; RISK FACTOR;

EID: 39149115032     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.05268.x     Document Type: Editorial

References (12)

1. Picardi A, D'Avola D, Gentilucci UV et al. Diabetes in chronic liver disease: from old concepts to new evidence. Diabetes Metab. Res. Rev. 2006 22 : 274 83.
2. McCaughan GW, Wickson JE, Creswick PF, Gorrell MD. Identification of the bile canalicular cell surface molecule GP110 as the ectopeptidase dipeptidyl peptidase IV: an analysis by tissue distribution, purification and N-terminal amino acid sequence. Hepatology 1990 11 : 534 44.
3. Itou M, Kawaguchi T, Taniguchi E et al. Altered expression of glucagon-like peptide and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance. J. Gastroenterol. Hepatol. 2008 23 : 253 60.
4. Amori RE, Lau J, Pittas AG. efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007 298 : 194 206.
5. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006 29 : 2638 43.
6. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Sitagliptin Study: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther. 2006 28 : 1556 68.
7. Samaras K, McElduff A, Twigg SM et al. Insulin levels in insulin resistance: phantom of the metabolic opera? Med. J. Aust. 2006 185 : 159 61.
8. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin. Sci. 2005 108 : 277 92.
9. Abbott CA, Yu DMT, Woollatt E, Sutherland GR, McCaughan GW, Gorrell MD. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur. J. Biochem. 2000 267 : 6140 50.
10. Thornberry NA, Weber AE. Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr. Top. Med. Chem. 2007 7 : 557 68.
11. Matsumoto Y, Bishop GA, McCaughan GW. Altered zonal expression of the CD26 antigen (dipeptidyl peptidase IV) in human cirrhotic liver. Hepatology 1992 15 : 1048 53.
12. Abbott CA, Gorrell MD, Kobayashi Y et al. Increased serum levels of dipeptidyl peptidase IV (CD26) in rats undergoing liver regeneration. Int. Hepatol. Commun. 1995 4 : 165 74.